GI Surgery – Liver
Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.
14 Jul, 2021 | 11:07h | UTCNews release: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Commentaries: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian AND Expert reaction to study of alcohol and cancer – Science Media Centre
AASLD Guideline: Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease.
28 Jun, 2021 | 09:33h | UTC
Guide to Enhanced Recovery for Cancer Patients Undergoing Liver Surgery
25 Apr, 2021 | 20:53h | UTCSee also: Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations – World Journal of Surgery AND Enhanced Recovery After Surgery (ERAS) Society Guidelines
Systematic review: Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease
23 Apr, 2021 | 08:17h | UTC
M-A: Treatment for bleeding esophageal varices in people with decompensated liver cirrhosis
12 Apr, 2021 | 00:39h | UTCRelated Cochrane Reviews: M-A: Secondary prevention of variceal bleeding in adults with previous esophageal variceal bleeding due to decompensated liver cirrhosis AND Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta‐analysis – Cochrane Library
Meta-Analysis: Primary prevention of variceal bleeding in people with esophageal varices due to liver cirrhosis
8 Apr, 2021 | 08:45h | UTCRelated Cochrane Review: M-A: Secondary prevention of variceal bleeding in adults with previous esophageal variceal bleeding due to decompensated liver cirrhosis
M-A: Secondary prevention of variceal bleeding in adults with previous esophageal variceal bleeding due to decompensated liver cirrhosis
5 Apr, 2021 | 01:17h | UTC
RCT: Mixed findings with Terlipressin plus Albumin for the treatment of Type 1 hepatorenal syndrome
4 Mar, 2021 | 08:35h | UTCTerlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: Albumin provides no benefit to hospitalized patients with decompensated cirrhosis
4 Mar, 2021 | 08:37h | UTCA Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Albumin provides no benefit to hospitalized patients with advanced liver disease – University College London
RCT: Hypothermic machine perfusion in liver transplantation
25 Feb, 2021 | 08:44h | UTCHypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cold Perfusion Cuts Liver Transplant Complications – MedPage Today
RCT: In patients with cirrhosis treated with TIPS, prophylactic rifaximin reduced the risk for Hepatic Encephalopathy
7 Feb, 2021 | 21:10h | UTCThe Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: A Randomized Controlled Trial – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Rifaximin prevents overt hepatic encephalopathy after TIPS – HealthDay
Commentary on Twitter
New findings published in @AnnalsofIM:
In patients with #cirrhosis treated with TIPS, rifaximin was well tolerated and reduced the risk for overt HE. #Rifaximin should therefore be considered for prophylaxis of post-TIPS HE https://t.co/d2p9dfcx3s. pic.twitter.com/M7zwmUxQA3
— Annals of Int Med (@AnnalsofIM) February 2, 2021